Randomized, Double‐Blind, Controlled Study of Cefoperazone‐Sulbactam Plus Cotrimoxazole versus Ceftazidime Plus Cotrimoxazole for the Treatment of Severe Melioidosis

• DOI: 10.1086/320878
• Publication Date: 2002-07-26T18:26:39Z
• Authors: Ploenchan Chetcho...; Sriurai Porramatikul; Piroon Mootsikapun; Siriluck Anunnatsiri; Bandit Thinkhamrop
• Keywords: Cefoperazone; Sulbactam; Sulfamethoxazole; Melioidosis; Trimethoprim

We conducted a prospective randomized, double-blind, controlled study of cefoperazone-sulbactam (ratio, 1 : 1; cefoperazone 25 mg/kg/day) plus cotrimoxazole (trimethoprim-sulfamethoxazole [TMP-SMZ] at ratio 80 400; TMP, 8 versus ceftazidime (100 (TMP, for the treatment severe melioidosis. Of 219 patients enrolled in study, 102 (47%) had culture-proven These were assigned randomly to 2 groups, each with 50 (2 excluded). Mortality rates not significantly different between groups: 18% group 14% group. The crude difference mortality rate was 4%, but when adjusted type infection 0.9% (95% confidence interval, −3.6% 5.4%; P = .696). duration defervescence and bacteriological response successfully treated similar both regimens well tolerated. Cefoperazone-sulbactam might be used as an alternative